- Home
- IVT vs TRVI Comparison
IVT vs TRVI Comparison
Compare IVT & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IVT | TRVI |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.6B |
| IPO Year | 2005 | 2019 |
Fundamental Metrics
Financial Performance| Metric | IVT | TRVI |
|---|---|---|
| Price | $36.66 | $19.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | ★ $32.50 | $21.55 |
| AVG Volume (30 Days) | 1.3M | ★ 2.9M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.14% | N/A |
| EPS Growth | ★ 647.37 | 31.91 |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $299,169,000.00 | N/A |
| Revenue This Year | $8.42 | N/A |
| Revenue Next Year | $5.25 | N/A |
| P/E Ratio | $523.43 | ★ N/A |
| Revenue Growth | ★ 9.20 | N/A |
| 52 Week Low | $26.81 | $6.55 |
| 52 Week High | $36.64 | $20.15 |
Technical Indicators
Market Signals| Indicator | IVT | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 66.90 | 60.37 |
| Support Level | $34.63 | $10.07 |
| Resistance Level | N/A | $20.15 |
| Average True Range (ATR) | 0.65 | 1.30 |
| MACD | 0.01 | -0.13 |
| Stochastic Oscillator | 77.99 | 68.09 |
Price Performance
Historical ComparisonAbout IVT InvenTrust Properties Corp.
InvenTrust Properties Corp is the United States of America based company qualified as a REIT (Real Estate Investment Trust). It is focused on owning, leasing, redeveloping, acquiring and managing a multi-tenant retail platform. The company's wholly-owned and managed retail properties include grocery-anchored community and neighborhood centers and power centers, including those classified as necessity-based. InvenTrust operates through a single segment i.e. multi-tenant retail.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.